Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status.

by Gillian Farnie, Pamela M Willan, Robert B Clarke, Nigel J Bundred
Published 2013-01-01

FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity

by Simon Timbrell, Hosam Aglan, Angela Cramer, Phil Foden, David Weaver, Jonathan Pachter, Aoife Kilgallon, Robert B. Clarke, Gillian Farnie, Nigel J. Bundred
Published 2021-05-01

Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study...

by John Castle, Emma Blower, Nigel J. Bundred, James R. Harvey, Jecko Thachil, Andrea Marshall, Karina Cox, Silvia Cicconi, Chris Holcombe, Carlos Palmieri, Cliona C. Kirwan
Published 2020-08-01

Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre‐invasive phenomena that is prognostic in invasion

by Hudhaifah Shaker, Nigel J. Bundred, Göran Landberg, Susan A. Pritchard, Harith Albadry, Sarah L. Nicholson, Lauren J. Harries, Jing Y. E. Heah, John Castle, Cliona C. Kirwan
Published 2020-03-01